Suppr超能文献

COVID-19 大流行对尿路感染和血流感染中产超广谱β-内酰胺酶大肠埃希菌的影响:来自全国监测网络的结果,芬兰,2018 年至 2022 年。

Impact of the COVID-19 pandemic on extended-spectrum β-lactamase producing Escherichia coli in urinary tract and blood stream infections: results from a nationwide surveillance network, Finland, 2018 to 2022.

机构信息

Department of Clinical Microbiology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

ISLAB Laboratory Centre, Kuopio, Finland.

出版信息

Antimicrob Resist Infect Control. 2024 Jul 6;13(1):72. doi: 10.1186/s13756-024-01427-z.

Abstract

BACKGROUND

Before the COVID-19 pandemic there has been a constant increase in antimicrobial resistance (AMR) of Escherichia coli, the most common cause of urinary tract infections and bloodstream infections. The aim of this study was to investigate the impact of the COVID-19 pandemic on extended-spectrum β-lactamase (ESBL) production in urine and blood E. coli isolates in Finland to improve our understanding on the source attribution of this major multidrug-resistant pathogen.

METHODS

Susceptibility test results of 564,233 urine (88.3% from females) and 23,860 blood E. coli isolates (58.8% from females) were obtained from the nationwide surveillance database of Finnish clinical microbiology laboratories. Susceptibility testing was performed according to EUCAST guidelines. We compared ESBL-producing E. coli proportions and incidence before (2018-2019), during (2020-2021), and after (2022) the pandemic and stratified these by age groups and sex.

RESULTS

The annual number of urine E. coli isolates tested for antimicrobial susceptibility decreased 23.3% during 2018-2022 whereas the number of blood E. coli isolates increased 1.1%. The annual proportion of ESBL-producing E. coli in urine E. coli isolates decreased 28.7% among males, from 6.9% (average during 2018-2019) to 4.9% in 2022, and 28.7% among females, from 3.0 to 2.1%. In blood E. coli isolates, the proportion decreased 32.9% among males, from 9.3 to 6.2%, and 26.6% among females, from 6.2 to 4.6%. A significant decreasing trend was also observed in most age groups, but risk remained highest among persons aged ≥ 60 years.

CONCLUSIONS

The reduction in the proportions of ESBL-producing E. coli was comprehensive, covering both specimen types, both sexes, and all age groups, showing that the continuously increasing trends could be reversed. Decrease in international travel and antimicrobial use were likely behind this reduction, suggesting that informing travellers about the risk of multidrug-resistant bacteria, hygiene measures, and appropriate antimicrobial use is crucial in prevention. Evaluation of infection control measures in healthcare settings could be beneficial, especially in long-term care.

摘要

背景

在 COVID-19 大流行之前,大肠杆菌的抗微生物药物耐药性(AMR)一直在持续增加,而大肠杆菌是尿路感染和血流感染最常见的病原体。本研究旨在调查 COVID-19 大流行对芬兰尿液和血液中产Extended-spectrum β-lactamase(ESBL)大肠杆菌分离株的影响,以提高我们对这一主要多药耐药病原体来源归因的认识。

方法

从芬兰临床微生物学实验室的全国监测数据库中获得了 564,233 份尿液(88.3%来自女性)和 23,860 份血液大肠杆菌分离株(58.8%来自女性)的药敏试验结果。药敏试验按 EUCAST 指南进行。我们比较了大流行前(2018-2019 年)、大流行期间(2020-2021 年)和大流行后(2022 年)产 ESBL 大肠杆菌的比例和发病率,并按年龄组和性别进行了分层。

结果

2018-2022 年,尿液大肠杆菌抗菌药物敏感性检测的年度样本数量减少了 23.3%,而血液大肠杆菌样本数量增加了 1.1%。男性尿液大肠杆菌分离株中产 ESBL 大肠杆菌的比例从 6.9%(2018-2019 年平均)下降了 28.7%,至 2022 年的 4.9%,女性从 3.0%下降了 28.7%,至 2.1%。血液大肠杆菌分离株中,男性的比例从 9.3%下降了 32.9%,至 6.2%,女性从 6.2%下降了 26.6%,至 4.6%。在大多数年龄组中也观察到了显著的下降趋势,但风险仍然最高的是年龄≥60 岁的人群。

结论

产 ESBL 大肠杆菌的比例下降全面,涵盖了两种标本类型、两种性别和所有年龄组,表明持续增加的趋势可能已经逆转。国际旅行和抗菌药物使用的减少可能是导致这一下降的原因,这表明在预防方面,向旅行者宣传多药耐药菌的风险、卫生措施和适当的抗菌药物使用至关重要。评估医疗机构的感染控制措施可能会有所帮助,尤其是在长期护理机构。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7187/11227720/18283ef18d14/13756_2024_1427_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验